The OncoAlert Newsletter
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
Related Articles
The Human Cost of Inaction on PBM Reform – DC Journal – InsideSources
The case against pharmacy benefit managers (PBMs) and for much-needed reforms of our broken prescription drug pricing system has been convincingly made.
A Woman’s Journey is empowering women to make informed health care decisions
Dr. Kendall Moseley joins us with information on bone health and how aging can affect women’s bone strength and loss.
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the…
What’s next in cancer care — Harvard Gazette
In the “Harvard Thinking” podcast, experts discuss advances in technology from genomic sequencing to AI to personalized vaccines.
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer
Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.
Trump picks Johns Hopkins surgeon Makary to run FDA
Makary is a close ally of Robert F. Kennedy Jr. and a proponent of his “Make America Healthy Again” movement to fight chronic diseases.
A simple suggestion for RFK Jr to end corruption in medicine
If you advise HHS you can’t stuff your pockets with Pharma cash
Astrogliosis and neuroinflammation underlie scoliosis upon cilia dysfunction
Brain ventricular astrogliosis and neuroinflammation precede scoliosis onset in the zebrafish rpgrip1l ciliary mutant and anti-inflammatory treatment drastically reduces scoliosis while correcting urotensin related peptide…
CAR-PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma | Dana-Farber Cancer Institute
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The…
Cancer specialist faked data in at least ten papers, VA and UCLA find
Alan Lichtenstein A multiple myeloma specialist “recklessly“ falsified data in at least 10 published articles, according to a joint investigation by the University of California,…